Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01912716 · ClinicalTrials.gov registry record · Phase 2
Rectal Indomethacin in the Prevention of Post-ERCP Pancreatitis
A Phase 2 study, sponsored by Indiana University.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,037
- Enrollment target
NCT01912716 is a Phase 2 study that has completed, run by Indiana University. The registered enrollment target is 1,037 participants.
The verdict
NCT01912716, a Phase 2 study, has completed, sponsored by Indiana University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,037 participants
- Enrollment target
Study Summary
It is now established that indomethacin, a non-steroidal anti-inflammatory drug, at a dose of 100 mg, is effective in reducing the frequency and severity of pancreatitis (inflammation of the pancreas) after endoscopic retrograde cholangiopancreatography (ERCP) in high risk patients. However, the optimal dose required is not known. The purpose of this study is to determine whether a dose of 200 mg, administered as rectal suppositories, is more effective than the standard dose of 100 mg. An ERCP procedure is a scope procedure where a lighted tube with a camera is passed down the patient's throat and allows for evaluation of the bile duct and/or pancreatic duct. The most common side effect of this procedure is post-ERCP pancreatitis, or swelling of the pancreas. Some patients are at higher risk for this complication than others. Our hypothesis is to compare the efficacy of these two dose regimens (100 mg vs 200 mg) of prophylactic rectally-administered indomethacin on the frequency and severity of post-ERCP pancreatitis in high-risk patients.
Interventions
- DRUG high dose indomethacin
- DRUG standard dose indomethacin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,037 participants |
| Start Date | 2013-07 |
| Est. Completion | 2018-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01912716
The ClinicalTrials.gov registry entry for NCT01912716 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1,037 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which high dose indomethacin is the first listed.
NCT01912716 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01912716 about?
NCT01912716 is a clinical study titled "Rectal Indomethacin in the Prevention of Post-ERCP Pancreatitis". It is now established that indomethacin, a non-steroidal anti-inflammatory drug, at a dose of 100 mg, is effective in reducing the frequency and severity of pancreatitis (inflammation of the pancreas) after endoscopic retrograde cholangiopancreatography (ERCP) in high risk patients. However, the opt...
What is the current status of trial NCT01912716?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,037 participants. The study started on 2013-07. Estimated completion is 2018-10.
What interventions are being tested in trial NCT01912716?
The interventions under investigation include: high dose indomethacin (DRUG), standard dose indomethacin (DRUG).
Who is sponsoring clinical trial NCT01912716?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.